Hostname: page-component-745bb68f8f-d8cs5 Total loading time: 0 Render date: 2025-02-06T13:59:22.698Z Has data issue: false hasContentIssue false
  • English
  • Français

Multichannel auditory brainstem implant: US clinical trial results

Published online by Cambridge University Press:  08 March 2006

K. Ebinger ,
S. Otto ,
J. Arcaroli ,
S. Staller  and
P. Arndt
K. Ebinger
Affiliation:
Clinical Studies Department, Cochlear Corporation, USA
S. Otto
Affiliation:
Clinical Studies Department, Cochlear Corporation, USA
J. Arcaroli
Affiliation:
Department of Auditory Implantable Prostheses, House Ear Institute, USA
S. Staller
Affiliation:
Clinical Studies Department, Cochlear Corporation, USA
P. Arndt
Affiliation:
Clinical Studies Department, Cochlear Corporation, USA
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Since 1994, a US Food and Drug Administration clinical trial evaluated the multichannel auditory brainstem implant (ABI) on 92 subjects with neurofibromatosis type 2 (NF2). The trial has shown that 85 per cent of patients receive auditory sensations. A small number of patients demonstrate a clinically significant degree of open-set sentence recognition in the sound-alone condition; however, when the ABI is combined with lip-reading cues, 93 per cent of patients demonstrate improved sentence understanding at three to six months. In addition, the majority of recipients report daily use of their devices, and satisfaction with the decision to receive the ABI.

Keywords

Brain StemProsthesis ImplantationNeurofibromatosis 2United States
Type
Research Article
Information
The Journal of Laryngology & Otology , Volume 114 , Issue S27 , December 2000 , pp. 50 - 53
Copyright
Royal Society of Medicine Press Limited 2000